CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia

Figures & data

Table I.  Sample characteristics.

Total number of patients	np/nt	%
Sex
Male	44/81	54.3
Female	37/81	45.7
Leukocyte ( × 10^3)
0-50	38/62	61.3
>50	24/62	38.7
Leukemia subtypes and controls
Bp-ALL	37/81	45.7
T-ALL	8/81	9.9
AML	17/81	21
Others*	9/81	11.1
Blood donors	10/81	12.3

*Non-leukemia cases were patients with others hematological alterations; np/nt = number of positive cases/number of cases tested.

Table II.  Antigen expressions according to CD26 presence or absence in patients with Bp-ALL, T-ALL and AML at diagnosis.

	CD26^+ve (np/nt) (%)	CD26^− ve (np/nt) (%)
Bp-ALL (n = 37)
CD19+/CD10 − /CD38 −	(0/2) (0)	(2/2) (100)
CD19+/CD10+/CD38 −	(28/35) (80)	(7/35) (20)
CD19+/CD10+/HLADr/CD38 +	(27/34) (79.4)	(7/34) (20.6)
T-ALL (n = 8)
cCD3+/CD5+/CD2 +	(4/5) (80)	(1/5) (20)
cCD3+/CD4+/CD8 −	(1/1) (100)	(0/1) (0)
cCD3+/CD4+/CD8 +	(2/3) (66.7)	(1/3) (33.3)
mCD3+/TdT+/CD38 +	(4/5) (80)	(1/5) (20.0)
AML (n = 17)	(7/12) (58.3)	(5/12) (41.7)
Total	(41/62) (66.1)	(21/62) (33.9)

(np/nt) number of positive cases/number of cases tested.

Table III.  Mean Percentage of antigens positive cells with respect to acute leukemia type.

	Bp-ALL (n = 37)	T-ALL (n = 8)	AML (n = 17)	Non-leukemia Control (n = 9)
Mean Percentage ± S.D. (np/nt) (%)
CD26+	48.6 ± 32.3 (78.4)	32.7 ± 39.3 (50.0)	25.3 ± 32.6 (41.2)	44.5 ± 33.7 (66.7)
CD19+	77.2 ± 24.1 (97.3)	2.3 ± 3.4 (0.0)	11.9 ± 21.1 (17.6)	25.2 ± 26.0 (33.3)
CD10+	78,6 ± 26.0 (94.6)	28.2 ± 39.6 (33.3)	2.76 ± 3.9 (0.0)	18.6 ± 33.4 (20)
CD2+	13.8 ± 17.2 (15.3)	61.6 ± 42.2 (71.4)	17.7 ± 20.5 (31.3)	42.4 ± 34.9 (55.6)
CD38+	85.2 ± 19.5 (97.3)	74.7 ± 33.2 (85.7)	72.6 ± 24.8 (100.0)	64.0 ± 27.1 (88.9)
TdT	74.1 ± 27.1 (94.6)	66.4 ± 45.5 (71.4)	5.29 ± 7.5 (5.9)	1.83 ± 3.0 (0.0)
HLADr	81.6 ± 20.9 (97.1)	4.0 ± 3.0 (0.0)	44.1 ± 30.8 (68.8)	36.1 ± 24.4 (77.8)
CD4+	17.6 ± 18.5 (36.4)	42.7 ± 40.8 (57.1)	26.9 ± 21.7 (52.9)	27.7 ± 18.9 (62.5)
CD8+	21.5 ± 18.6 (42.9)	38.4 ± 30.5 (71.4)	28.0 ± 27.0 (52.9)	22.1 ± 18.2 (55.6)
cCD3+	20.0 ± 22.6 (33.3)	91.3 ± 11.1 (100)	15.8 ± 21.2 (25)	38.3 ± 32.8 (50)
mCD3+	13.0 ± 13.4 (16.2)	37.1 ± 29.7 (71.4)	11.2 ± 14.6 (25)	44.4 ± 36.1 (55.6)
CD1a+	2.64 ± 6.0 (5.6)	28.7 ± 39.5 (42.9)	3.0 ± 5.2 (0.0)	0.5 ± 1.2 (0.0)
CD5+	9.5 ± 14.5 (11.1)	70.7 ± 32.2 (85.7)	14.0 ± 22.3 (23.5)	39.3 ± 32.6 (55.6)
CD13+	7.8 ± 18.1 (11.1)	32.4 ± 40.9 (42.9)	38.1 ± 27.7 (70.6)	2.3 ± 1.5 (0.0)
CD33+	20.2 ± 21.0 (35.1)	2.0 ± 3.4 (0.0)	53.7 ± 31.4 (88.2)	4.4 ± 1.5 (0.0)
CD45+	65.4 ± 28.5 (86.5)	73.8 ± 37.1 (83.3)	68.1 ± 33.3 (82.4)	67.1 ± 37.8 (75)
CD34+	43.4 ± 33.2 (67.6)	0.57 ± 0.79 (0.0)	41.7 ± 34.9 (64.7)	0.8 ± 1.8 (0.0)

(np/nt) number of positive cases/number of cases tested.

Table IV.  Percentage of antigen positive cells with respect to immunophenotype and DPPIV activity in the plasma.

	Bp-ALL (n = 36)		T-ALL (n = 6)		AML (n = 16)		Non-leukemia Control (n = 9)
	^aDPPIV^+ (n = 7)	^bDPPIV^+ (n = 29)	^aDPPIV^+ (n = 1)	^bDPPIV^+ (n = 5)	^aDPPIV^+ (n = 6)	^bDPPIV^+ (n = 10)	^aDPPIV^+ (n = 4)	^bDPPIV^+ (n = 5)
Mean Percentage ± S.D.
CD26+	64.79 ± 28.21	46.40 ± 31.87	0	38.86 ± 42.79	18.57 ± 23.08	29.71 ± 39.22	60.88 ± 25.56	31.38 ± 35.96
CD19+	88.29 ± 7.18	74.17 ± 26.28	9.00	1.00 ± 1.00	4.17 ± 6.55	17.70 ± 26.03	6.50 ± 3.54	34.50 ± 27.97
CD10+	87.43 ± 5.94	76.17 ± 28.85	0	56.00 ± 39.85	2.33 ± 3.01	2.80 ± 4.61	1.50 ± 0.71	30.00 ± 41.76
CD2+	18.86 ± 18.95	12.75 ± 17.2	0	86.25 ± 5.68	7.33 ± 3.88	23.11 ± 25.41	36.75 ± 36.25	47.00 ± 37.30
CD38+	83.43 ± 30.94	86.03 ± 16.59	97.00	84.25 ± 12.69	61.33 ± 26.07	77.90 ± 24.03	61.67 ± 27.54	65.40 ± 29.98
TdT	72.0 ± 20.78	74.03 ± 29.05	0	93.25 ± 4.99	6.67 ± 7.03	4.70 ± 8.43	0	2.75 ± 3.40
HLADr	91.17 ± 6.76	79.32 ± 22.74	5.00	3.75 ± 2.63	41.50 ± 33.97	49.78 ± 29.31	37.25 ± 24.81	35.20 ± 26.96
CD4+	18.71 ± 18.95	16.80 ± 19.74	6.00	72.00 ± 25.68	22.33 ± 18.15	27.50 ± 24.20	29.33 ± 20.11	26.80 ± 20.56
CD8+	25.0 ± 11.75	20.96 ± 20.36	24.00	50.50 ± 33.17	34.67 ± 27.44	26.70 ± 27.62	23.50 ± 22.59	21.00 ± 16.55
cCD3+	20.29 ± 26.35	19.29 ± 22.25	82.00	97.25 ± 1.71	4.67 ± 6.02	15.33 ± 9.86	42.50 ± 44.55	36.25 ± 33.36
mCD3+	18.14 ± 20.38	11.90 ± 11.61	90.00	30.50 ± 17.48	2.80 ± 2.17	16.00 ± 16.83	43.25 ± 39.68	45.40 ± 37.82
CD1a+	0.17 ± 0.41	3.21 ± 6.55	0	50.00 ± 41.37	0.05 ± 0.55	4.67 ± 6.60	0	0.75 ± 1.50
CD5+	13.43 ± 15.01	8.68 ± 14.70	85.00	81.25 ± 11.21	3.17 ± 2.64	13.50 ± 16.01	31.50 ± 30.60	45.60 ± 36.21
CD13+	5.29 ± 7.02	7.21 ± 19.19	89.00	14.75 ± 28.17	40.33 ± 27.26	35.50 ± 30.32	1.00 ± 0	3.00 ± 1.41
CD45+	64.14 ± 28.0	64.72 ± 29.08	99.00	87.33 ± 9.71	41.00 ± 27.34	82.30 ± 28.28	50.33 ± 35.12	77.20 ± 39.26
CD34+	38.71 ± 24.31	43.17 ± 35.09	0	1.00 ± 0.82	34.17 ± 28.66	43.80 ± 40.06	0	1.33 ± 2.31
CD33+	29.14 ± 24.42	18.10 ± 20.43	1.00	3.25 ± 4.03	52.67 ± 36.51	54.70 ± 31.71	5.50 ± 2.12	3.67 ± 0.58
CD61+	2.71 ± 3.60	2.17 ± 3.37	0	6.50 ± 13.00	0.50 ± 0.55	6.00 ± 10.83	3.50 ± 4.95	9.00 ± 10.23

^a DPPIV activity in plasma is between 0.2 and 0.6 U/mg total protein

^b DPPIV activity in plasma is higher than >0.6 U/mg total protein.

n = number of patients or controls.

Figure 1.  Mutual relation among the DPPIV plasma activity of patients of acute leukemia and the CD26 expression status in each case. The DPPIV plasma activity was plotted in relation to CD26 < 20% and >20% expression in mononuclear cells for each type of leukemia tested. Non-leukemic cases were patients with others hematological alterations and control were samples from healthy donors.